TREATMENT OF HYPERTENSIVE PATIENTS WITH HIGH OR VERY HIGH CARDIOVASCULAR RISK. PHARMACOECONOMIC EFFICIENCY OF A TRIPLE COMBINATION THERAPY CONTAINING ANGIOTENSIN CONVERTING ENZYME INHIBITOR, CALCIUM CHANNEL BLOCKER AND STATIN
Arterial hypertension (AH) is one of the most common cardiovascular diseases and a frequent cause of cardiovascular complications and early disability. In Russia, AH of varying severity may affect about 30% of the population. [1] Hypertension is the causal factor for 27% of cardiovascular events in...
Main Author: | I. N. DYAKOV |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2016-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/1353 |
Similar Items
-
Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
by: Valentina Carubelli, et al.
Published: (2021-06-01) -
Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
by: Michael Pan, et al.
Published: (2021-12-01) -
Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?
by: Imdat Eroğlu, et al.
Published: (2020-07-01) -
Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01) -
Angiotensin‐converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta‐analysis
by: Yiyun Hu, et al.
Published: (2023-08-01)